Bone repair product and methods of use thereof
US-10729809-B2 · Aug 4, 2020 · US
US12310993B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12310993-B2 |
| Application number | US-201816229823-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 21, 2018 |
| Priority date | Jun 24, 2016 |
| Publication date | May 27, 2025 |
| Grant date | May 27, 2025 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed are compositions comprising a non-homogenized chorionic matrix, a homogenized amniotic matrix and a homogenized UC (UC) matrix, wherein the non-homogenized chorionic matrix comprises viable cells. Disclosed are methods of making the compositions disclosed herein comprising preparing a non-homogenized chorionic matrix, preparing a homogenized amniotic matrix, preparing a homogenized UC matrix, and combining the non-homogenized chorionic matrix, the non-homogenized chorionic matrix, and the homogenized UC matrix. Disclosed are methods of treating a tissue injury or chronic pain comprising administering any of the disclosed compositions to an area of a subject comprising a tissue injury.
Opening claim text (preview).
We claim: 1. A composition comprising a minced chorionic matrix and a devitalized homogenized umbilical cord (UC) matrix, wherein the minced chorionic matrix comprises native cells, wherein the composition does not comprise trophoblasts or an amniotic matrix, wherein the composition is lyophilized, wherein at least 70% of the native cells of the minced chorionic matrix are viable after storage at room temperature in the lyophilized state, wherein the minced chorionic matrix and the devitalized homogenized UC matrix are each in particulate form, wherein the minced chorionic matrix has a larger average particle size than the devitalized homogenized UC matrix, and wherein the devitalized homogenized UC matrix does not include Wharton's jelly. 2. The composition of claim 1 , wherein the composition is formulated as a cream, gel, oil, ointment, or lotion. 3. The composition of claim 1 further comprising viable, isolated amniotic cells. 4. The composition of claim 1 , wherein the homogenized UC matrix is not decellularized. 5. The composition of claim 1 , wherein the minced chorionic matrix is not homogenized. 6. The composition of claim 1 , wherein the composition comprises viable chorionic stem cells, amniotic stem cells, fibroblasts, epithelial cells or a combination thereof. 7. The composition of claim 1 , wherein the minced chorionic matrix and homogenized UC matrix are from the same donor. 8. The composition of claim 1 , wherein the homogenized UC matrix comprises de-veined UC tissue. 9. The composition of claim 1 , wherein the minced chorionic matrix comprises greater than or equal to 100,000 viable cells/ml. 10. The composition of claim 1 , wherein at least 75% of the native cells of the minced chorionic matrix are viable after storage at room temperature in the lyophilized state. 11. The composition of claim 1 , wherein the composition further comprises a pharmaceutically acceptable excipient. 12. The composition of claim 1 , wherein the homogenized UC matrix is 10 nm to 1 mm in size. 13. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.
Umbilical cord; Umbilical cord blood; Umbilical stem cells · CPC title
Ingredients of undetermined constitution or reaction products thereof · CPC title
Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells · CPC title
characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel · CPC title
for joint disorders, e.g. arthritis, arthrosis · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.